Italbiotec helps companies access funds and grants for R&S
Managing Director Bosco: 'Growth will have to come from strengthening by external lines with new acquisitions
by Enrico Netti
3' min read
3' min read
Helping companies in the not easy path leading to access to funds and contributions for research, development and innovation. The activities of Italbiotec, a Milan-based benefit company operating in the life sciences, agri-food and bio-economy sectors, move within this facilitator perimeter. Its core activities include innovation management, which streamlines research and development processes through technical analyses, business plans, sustainability studies and scientific training; and auditing and reporting, which ensures financial control and correctness in the management of funded projects.
Italbiotec has a business plan that, in addition to research, envisages the expansion of its presence in Italy and abroad, focusing on human resources with the aim of expanding the team. Over the next five years, the plan envisages the opening of offices in markets such as Belgium, Switzerland and France, the United States and the United Arab Emirates, in order to get closer to strategic bio-economy markets and expand the ecosystem of sustainable innovation in the life sciences, agri-food and biotechnology sectors. Also in the field is a strategy of acquisitions of realities specialising in R&D, from scientific validation to regulatory affairs and Ai for the digitalisation of biotech processes, in order to build an increasingly articulated and modular platform of integrated services, capable of responding to the complex needs of companies, start-ups and public stakeholders on a global level.
The company achieved a turnover of EUR 2.2 million in 2024 with +55% compared to 2023. Equally positive is the Ebitda trend at 674,000 Euro with +165% compared to the previous year.
"We have been able to seize the opportunities offered by the bio-economic transition and invest with farsightedness in projects of high impact, both scientific and industrial," emphasises Diego Bosco, Italbiotec's CEO. "This balance sheet is not just an economic result: it is confirmation that our vision is capable of generating real and lasting value for our stakeholders, for the territory, and for the entire ecosystem of innovation. As far as the near future is concerned, the CEO sees 2025 as a year of growth 'with the strengthening of international activities, the activation of new strategic partnerships, investments in R&D, sustainability, digitalisation, and an important internal human resources development plan with the attraction of new talent,' Bosco continues. 'Growth will also pass through a strengthening by external lines, with the forecast of new acquisitions in Italy and abroad to broaden the scope of action from here to the coming years.
The balance. "is provisional" warns Bosco of the first half of 2025 sees Pmi continuing along the development path followed in recent years. "The picture is positive and will see us grow in double figures again in 2025, mainly thanks to the increase in technology transfer activities, the consolidation of academic and industrial partnerships and a strengthening of our positioning at European level."
